| An overview of chitosan nanoparticles and its application in non-parenteral drug delivery MA Mohammed, JTM Syeda, KM Wasan, EK Wasan Pharmaceutics 9 (4), 53, 2017 | 1318 | 2017 |
| Review and analysis of FDA approved drugs using lipid-based formulations R Savla, J Browne, V Plassat, KM Wasan, EK Wasan Drug development and industrial pharmacy 43 (11), 1743-1758, 2017 | 256 | 2017 |
| Biological barriers to cellular delivery of lipid-based DNA carriers MB Bally, P Harvie, FMP Wong, S Kong, EK Wasan, DL Reimer Advanced drug delivery reviews 38 (3), 291-315, 1999 | 241 | 1999 |
| Chitosan nanoparticles at the biological interface: implications for drug delivery N Aibani, R Rai, P Patel, G Cuddihy, EK Wasan Pharmaceutics 13 (10), 1686, 2021 | 204 | 2021 |
| Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese GNC Chiu, SA Abraham, LM Ickenstein, R Ng, G Karlsson, K Edwards, ... Journal of Controlled Release 104 (2), 271-288, 2005 | 149 | 2005 |
| The functional roles of poly (ethylene glycol)‐lipid and lysolipid in the drug retention and release from lysolipid‐containing thermosensitive liposomes in vitro and in vivo B Banno, LM Ickenstein, GNC Chiu, MB Bally, J Thewalt, E Brief, ... Journal of pharmaceutical sciences 99 (5), 2295-2308, 2010 | 143 | 2010 |
| Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with … EK Wasan, K Bartlett, P Gershkovich, O Sivak, B Banno, Z Wong, ... International journal of pharmaceutics 372 (1-2), 76-84, 2009 | 143 | 2009 |
| Highly effective oral amphotericin B formulation against murine visceral leishmaniasis KM Wasan, EK Wasan, P Gershkovich, X Zhu, RR Tidwell, KA Werbovetz, ... Journal of Infectious Diseases 200 (3), 357-360, 2009 | 110 | 2009 |
| Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation P Gershkovich, EK Wasan, M Lin, O Sivak, CG Leon, JG Clement, ... Journal of antimicrobial chemotherapy 64 (1), 101-108, 2009 | 99 | 2009 |
| Plasmid DNA is protected against ultrasonic cavitation‐induced damage when complexed to cationic liposomes EK Wasan, DL Reimer, MB Bally Journal of pharmaceutical sciences 85 (4), 427-433, 1996 | 99 | 1996 |
| Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the … K Sachs-Barrable, SD Lee, EK Wasan, SJ Thornton, KM Wasan Advanced drug delivery reviews 60 (6), 692-701, 2008 | 97 | 2008 |
| Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes J Woo, GNC Chiu, G Karlsson, E Wasan, L Ickenstein, K Edwards, ... International journal of pharmaceutics 349 (1-2), 38-46, 2008 | 90 | 2008 |
| Use of temperature to control the size of cationic liposome/plasmid DNA complexes EK Wasan, MB Bally, MJ Hope, DL Reimer, QF Ahkong US Patent 5,965,542, 1999 | 74 | 1999 |
| The development of oral amphotericin B to treat systemic fungal and parasitic infections: has the myth been finally realized? G Cuddihy, EK Wasan, Y Di, KM Wasan Pharmaceutics 11 (3), 99, 2019 | 70 | 2019 |
| A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model EK Wasan, P Gershkovich, J Zhao, X Zhu, K Werbovetz, RR Tidwell, ... PLoS neglected tropical diseases 4 (12), e913, 2010 | 69 | 2010 |
| A multi-step lipid mixing assay to model structural changes in cationic lipoplexes used for in vitro transfection EK Wasan, P Harvie, K Edwards, G Karlsson, MB Bally Biochimica et Biophysica Acta (BBA)-Biomembranes 1461 (1), 27-46, 1999 | 53 | 1999 |
| An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics. 2017; 9 (4): 53 MA Mohammed, JTM Syeda, KM Wasan, EK Wasan | 51 | |
| Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers DN Waterhouse, KA Gelmon, R Klasa, K Chi, D Huntsman, E Ramsay, ... Current cancer drug targets 6 (6), 455-489, 2006 | 50 | 2006 |
| Lipid/DNA complexes as an intermediate in the preparation of particles for gene transfer: an alternative to cationic liposome/DNA aggregates MB Bally, YP Zhang, FMP Wong, S Kong, E Wasan, DL Reimer Advanced drug delivery reviews 24 (2-3), 275-290, 1997 | 46 | 1997 |
| Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan SJ Thornton, KM Wasan, A Piecuch, LLD Lynd, EK Wasan Drug development and industrial pharmacy 36 (11), 1312-1319, 2010 | 39 | 2010 |
